Wet AMD
04.06.21
ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ VisionSource: ForeseeHome
03.31.21
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for LytenavaSource: Outlook Therapeutics
03.18.21
After the American Academy of Ophthalmology’s Urging, Blue Cross Blue Shield Clarifies Eylea PolicySource: American Academy of Ophthalmology
03.09.21
Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDSource: Adverum Biotechnologies
03.09.21
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO TrialSource: Graybug Vision
03.08.21
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD PatientsSource: Alteogen
03.02.21
Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDSource: Clearside Biomedical
02.23.21
Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical TrialsSource: Asclepix Therapeutics
02.16.21
Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular DiseasesSource: Kodiak Sciences